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BACKGROUND: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used
methods to assess HER2 status. PCR-based assays allow quantitative determination of HER2 amplification (Q-PCR) or
overexpression (Q-RT–PCR), but are not routinely used. We evaluated the relevance of Q-RT–PCR for HER2 status
determination.
METHODS: We compared IHC and Q-RT–PCR in 466 breast tumours. In discordant or equivocal cases, five additional methods (IHC
with two other antibodies, FISH, silver in situ hybridisation (SISH) and Q-PCR) were combined to determine HER2 status. Two cases
with HER2 intra-tumour heterogeneity were further explored by allelic profiles analysis and HUMARA clonality determination after
microdissection.
RESULTS: We observed 97.3% concordance between Q-RT–PCR and non-equivocal IHC. Twelve out of 466 cases (3%) revealed
discordances between the two methods. The power of Q-RT–PCR to predict HER2 status (defined by seven methods) was similar
to that of IHC. Although rare, some discordances between techniques might be due to HER2 intra-tumour heterogeneity and we
report two examples, one tumour containing two distinct clones, another tumour consisting of HER2 amplified and non-amplified
subclones.
CONCLUSION: Q-RT–PCR and IHC are highly concordant methods for HER2 status assessment, and Q-RT–PCR allows a highly
reliable quantitative assessment and could be a useful adjunct to IHC.
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The HER2 gene encodes the human epidermal growth factor
receptor 2 with tyrosine kinase activity (Slamon et al, 1987) and is
overexpressed in 15–20% of breast cancers (Owens et al, 2004),
through gene amplification with well correlated level of protein
expression (Pauletti et al, 1996; Yarden, 2001). This molecular
abnormality defines breast tumours with poor prognosis and
increased risk of early relapse (Slamon et al, 1987, 1989), but
predicts response to the humanised monoclonal anti-HER2
antibody trastuzumab (Herceptin) or to small tyrosine kinase
inhibitors such as lapatinib or erlotinib.
The increasing number of patients with breast cancer whose
survival has been improved by trastuzumab treatment underlines
the need for sensitive, specific, highly reproducible and
cost-efficient methods to identify patients eligible for anti-HER2
therapies. Furthermore, HER2 status not only predicts anti-HER2
efficacy, but could also determine other treatment options. Indeed,
HER2-overexpressing breast tumours are often resistant to
hormonotherapy and more sensitive to anthracycline-based and
taxane-containing chemotherapy (Paik et al, 2000; Pritchard et al,
2008), so that all invasive breast cancer need an HER2 evaluation at
diagnosis.
In daily practice, according to the American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAPs) recom-
mandations (Wolff et al, 2007), HER2 status is determined by
immunohistochemistry (IHC) followed, if necessary, by fluores-
cent in situ hybridisation (FISH), although FISH first-line
determination is also encouraged by some authors (Sauter et al,
2009). Immunohistochemistry results are obtained on formalin-
fixed paraffin-embedded (FFPE) samples and expressed as a four-
scale score system (0 to 3þ). Determination of HER2 status by
FISH is also performed on FFPE samples. It shows the mean
number of HER2 copies using a DNA probe hybridising to the
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sHER2 gene alone or in association with a centromeric probe as
control for chromosome 17 copy number expressed as HER2/
CEN17 ratio. Fluorescent in situ hybridisation is now challenged
by chromogenic (CISH) or silver in situ hybridisation (SISH),
faster methods using a chromogenic signal that do not decay over
time, that can be further reevaluated and need only a classical light
microscope (Isola et al, 2004; Laakso et al, 2006; Papouchado et al,
2010). A ‘gold standard’ for HER2 determination does not really
exist and the ASCO/CAPs study estimates that 20% of current
HER2 tests may be inaccurate owing to multiple preanalytic and
analytic variables (Wolff et al, 2007). Indeed, the existence of
various IHC protocols, FDA-approved antibodies or probes
contributes to interlaboratory variability. Improvement in HER2-
testing reproducibility between laboratories is crucial and new
HER2-testing technologies are also needed.
Different studies have evaluated the performance of Q-RT–PCR
or Q-PCR to determine the HER2 status (Laudadio et al, 2007).
Quantitative PCR using primers flanking the HER2 gene or mRNA
can quantify gene amplification or messenger overexpression.
PCR-based assays are easy, rapid, sensitive, specific and quanti-
tative approaches without the inherent inter-observer variability of
IHC and FISH/CISH techniques. It can be used on small samples
and can be standardised and automated. DNA extraction can also
be performed on FFPE tissues. However, RT–PCR technology,
more sensitive to RNA quality, is more robust if frozen tissues are
used. The main PCR drawback is that DNA or RNA extraction
mixes tumour and non-tumour cells and can lead to tumour cells
dilution with risk of false negative. Conversely, the mix of invasive
tumour cells with high-grade intraductal HER2-positive tumour
cells can lead to false positive results. Provided that sample purity
is controlled with microscopical examination, PCR-based deter-
mination has been shown to correlate well with IHC and FISH
(Vinatzer et al, 2005; Barberis et al, 2008).
In order to evaluate the benefits of PCR-based technology in
daily HER2 testing, we performed a large prospective study
comparing HER2 determination with IHC and Q-RT–PCR. As
recommended in guidelines, IHC 2þ cases were further explored
not only by FISH and SISH but also by other IHC tests and Q-PCR.
Moreover, all discordant cases were explored by these additional
techniques. We also analysed extensively two cases showing
striking HER2 intra-tumour heterogenity that may explain some
technical discordances.
We observed that molecular approaches are powerful and
reliable quantitative tools for HER2 status assessment that could
complement IHC for optimal patient care.
MATERIALS AND METHODS
Patients and samples
We analysed 466 primary breast tumours obtained from patients
treated in Saint Louis Hospital (Paris) from 2002 to 2007. All patients
were informed of the study according to our Institutional Review
Board recommendations. A total of 332 samples were obtained from
surgical specimen and 134 were obtained with fine-needle biopsies.
Tumours with 410% in situ component were excluded from this
study. Haematoxylin–eosin (H&E) stainings, immunohistochemical
stainings and in situ hybridisation techniques were performed on
FFPE tissue samples. Q-RT–PCR and Q-PCR were performed on
RNA and DNA extracted from frozen tissues.
IHC detection
HER2 immunohistochemistry was performed with the monoclonal
HER2 CB11 antibody (Novocastra, Newcastle upon Tyne, UK,
dilution 1/250) in the BenchmarkXT immunostainer (Roche
Diagnostics, Basel, Switzerland) with calibrated positive controls
and internal (on slide) negative controls. Evaluation of immunos-
tainings was performed by two pathologists (PB, AR) and scored
according to ASCO guidelines (Wolff et al, 2007; Gown, 2008):
negative for 0 (no membrane staining) and 1þ (faint or barely
perceptible incomplete membrane staining); equivocal for 2þ
(10–30% tumour cells with strong complete membrane staining or
410% tumour cells with moderate complete membrane staining)
and positive for 3þ (430% tumour cells with strong complete
membrane staining).
For discordant and CB11 equivocal cases, HER2 immunohisto-
chemistry was performed with A0485 polyclonal (Dako, Glostrup,
Denmark, dilution 1/500) and 4B5 monoclonal antibody (Roche
Diagnostics, prediluted) using the Discovery immunostainer (Roche
Diagnostics). HER2 scores were evaluated as described below.
Other antibodies were used with the Discovery immunostainer:
oestrogen receptor (Novocastra, clone 6F11, dilution 1/50),
progesteron receptor (Novocastra, clone 312, dilution 1/75),
cytokeratin 5/6 (Dako, clone B4, dilution 1/50), cytokeratin 17
(Dako, clone E30, dilution 1/50) and cytokeratin 8 (Millipore,
Billerica, MA, USA, clone MAB 3414, 1/50).
SISH and FISH detection
Silver in situ hybridisation and FISH were performed on 3mm
paraffin tissue sections. Silver in situ hybridisation staining, with
HER2 and chromosome 17 probes, was performed in Bench-
markXT slide stainers (Roche Diagnostics) and described in Dietel
et al (2007). Fluorescent in situ hybridisation staining was
performed using the Zytolight Spec HER2/CEN17 kit (Zytovision,
CliniScience, Montrouge, France) according to the manufacturer’s
protocol. Fluorescence signal were counted by one pathologist
(MA) using a (Leica DM 4000) Zeiss Axioscope Imager Z1
fluorescence microscope (Zeiss, Oberkochen, Germany). A minimum
of 80 tumour cell nuclei, with intact morphology according to
DAPI counterstaining, were counted. The HER2/CEN17 ratio was
obtained by dividing the mean number of HER2 signals by the
mean number of CEN17 signals in tumour cells and defined HER2
gene amplification if 42.2, equivocal if between 1.8 and 2.2 and no
HER2 amplification if o1.8, according to ASCO/CAPs recommen-
dations (Wolff et al, 2007).
Quantification of HER2 overexpression by Q-RT–PCR and
HER2 gene copy number by Q-PCR
Nucleic acids were extracted by phenol/chloroform procedure.
Tumour cell purity and presence of in situ carcinoma were
assessed on adjacent H&E-stained sections. Quantitative PCR were
performed on LightCycler 2.1 instrument (Roche Diagnostics).
HER2 overexpression was evaluated by relative quantification
using TATA-binding protein as endogen control (Bossard et al,
2005). Final result was expressed as a normalised ratio considered
as over-expressed if 47. The cut-off ratio was determined on a
tumours training set using univariate partition method (XLSTAT
software) and correlation with IHC–HER2 expression. HER2
amplification was evaluated on DNA using the LightCycler-HER-2/neu
DNA Quantification kit (Roche Diagnostics) in all IHC2þ and
IHC/Q-RT–PCR discordant specimens. The assay amplifies
simultaneously one HER2 fragment and one gastrin fragment,
the reference gene localised on the chromosome 17. Results were
expressed as the ratio of HER2/gastrin in the sample, normalised
with the same ratio in the calibrator DNA set. A ratio above 2 was
considered amplified. Results between 2 and 3 were repeated.
Allelic profiles analysis
Allelic profiles were analysed as described in Varna et al (2007).
We used a PALM Microbeam/Olympus system to perform laser
tissue microdissection on FFPE tissue sections. PCR was
performed directly on cell lysates with at least 500 cells for each
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D17S855, D17S1840, D13S153 and D9S171. Whole tumour allelic
profiles and microdissected areas allelic profiles were compared.
Clonality assessment using androgen receptor gene
methylation pattern
The androgen receptor gene (HUMARA) polymorphism is
characterised by highly polymorphic short-tandem CAG repeat
units, 100bp downstream of a methylated site in the coding region
of its first exon (Lucas et al, 1997; Fujita et al, 1998; Wang et al,
2007). Before digesting the genomic DNA with methylation-
sensitive restriction enzyme HpaII, electrophoresis of heterozygote
cases shows two alleles. After digesting the genomic DNA with
HpaII, electrophoresis shows two different alleles if the tumour is
not monoclonal and only one allele or at least strong allelic
imbalance if the tumour is of monoclonal origin due to
X-chromosome inactivation mosaicism, as solely the inactive
methylated allele is not cut at the restriction site and hence PCR
amplified.
Tumour DNA was amplified at the HUMARA locus either with
or without HpaII predigestion and overall tumour profiles and
microdissected areas profiles were compared.
RESULTS
IHC and Q-RT–PCR comparisons
To determine HER2 status, we performed immunohistochemistry
with CB11 antibody and Q-RT–PCR on all 466 cases (Figure 1).
Overall concordance was excellent (97.3%), especially in IHC 0,1þ
subgroup (348 negative Q-RT–PCR/351 IHC 0/1þ: 99.2%).
Concordance was also good in IHC 3þ cases (91%: 92 positive
Q-RT–PCR/101 IHC 3þ). However, in 12 out of 466 cases (3%),
the two techniques were discordant (either IHC 0,1þ/Q-RT–
PCR47 or IHC 3þ/Q-RT–PCRo7). Among these 12 discordant
cases, 11 had been obtained after surgical procedure and only one
after fine-needle biopsy. In the 14 out of 466 IHC 2þ equivocal
cases, Q-RT–PCR showed the absence of HER2 overexpression in
13 out of 14 cases (93%).
Analysis of the 26 discordant or equivocal cases
According to guidelines, all IHC score 2þ (n¼14) were analysed
not only by hybridisation methods (FISH and SISH), but also with
two other IHC–HER2 antibodies and Q-PCR (Figure 2). These
additional methods were also performed in all discordant cases
(n¼12). An overall HER2 status was defined for each of these 26
discordant or equivocal cases, based on the results of all seven
techniques used, a case being HER2 positive if there were more
positive than negative results (12 out of 26 cases), being negative if
there were more negative than positive results (12 out of 26 cases)
and being HER2 unclassified in other situations (2 out of 26 cases).
Among the 14 equivocal cases, 4 were finally scored positive by the
overall HER2 status, 9 negative and 1 remained undefined. In these
equivocal cases, Q-RT–PCR analysis predicted the final HER2
status in 10 cases and failed in only 3 cases. However, in the 12
discordant cases, Q-RT–PCR predicted final HER2 status in only
two cases and failed in nine cases.
The overall ability of Q-RT–PCR to predict final HER2 status in
the 24 cases with known final HER2 status was, therefore, 12 out of
24, while the overall ability of IHC CB11 to predict final HER2
status was 9 out of 24. Accordingly, Q-RT–PCR and IHC,
respectively, predicted the overall HER2 status in 452 tumours
and in 449 tumours. Among the 26 IHC/Q-RT–PCR discordant or
IHC 2þ cases, only six tumours (#1, 2, 14, 23, 24 and 25) showed
highly concordant results, with 6 out of 7 methods showing similar
results. The other 20 cases all showed more extensive discrepancies
among the techniques used, with only three to five concordant
methods. The results in case #4, either positive or borderline, were
possibly due to chromosome 17 polysomy that was demonstrated
with FISH and SISH techniques. In case #17 (Figure 2B), we
observed heterogeneous IHC staining among the three antibodies
used, as well as FISH negativity and moderate amplification with
SISH. In the other cases, no easy explanation could be given for
these technical discrepancies and either borderline HER2 status or
true intra-tumour heterogeneity could be implicated.
Phenotype and genotype analyses of two cases with HER2
intra-tumour heterogeneity
In order to explore one possible cause of discordances between
techniques, we analysed two cases that showed obvious intra-
tumour HER2 heterogeneity.
In Case A, H&E examination showed the presence of a 1-cm less
differentiated area (area 1) located inside the main tumour
component (area 2) (Figure 3A). Area 1 was scored 3þ for
HER2, was positive for CK5/6 and negative for ER, PR, CK8 and
CK17, while area 2 was negative for HER2, CK5/6 and CK17 and
positive for ER, PR and CK8. Silver in situ hybridisation confirmed
HER2 amplification only in tumour cells of area 1 (Figure 3A).
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Figure 1 Comparison of HER2 determination by IHC (CB11) and Q-RT–PCR on 466 breast tumours treated in St Louis Hospital. (A) Distribution of
tumour samples according to HER2 status assessed on formalin-fixed, paraffin-embedded samples with 0/1þ,2þ and 3þ IHC scores and Q-RT–PCR on
fresh frozen samples, with a cut-off ratio of 7. (B) HER2 Q-RT–PCR ratio according to the three IHC score groups: each box shows the 25–75th percentile
(box extremities), the median values (line in the box and value outside) and the lowest and highest values (bottom and top bars of the whisker).
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not shown). Allelic profiles with the other microsatellites were
either non-informative or showed no significant difference
between the two areas (data not shown). The analysis of the
X-chromosome methylation pattern showed important differences
between areas 1 and 2 (Figure 3B): before HpaII digestion, allelic
profiles showed LOH in each area, but on two distinct alleles. After
HpaII digestion, profiles showed inactivation of one X chromo-
some in both areas 1 and 2, indicating that both areas are
populated by monoclonal cells. However, areas 1 and 2 did not
inactivate the same X chromosome, demonstrating that they are
not deriving from the same clone.
In Case B (case #18 of this study), HER2 immunohistochemical
staining (Figure 4A) showed two sharply demarcated areas, one
with a strong membranous staining in over 80% of tumour cells
(area 1) and one totally negative (area 2). These two areas looked
totally similar on H&E staining. Other immunostainings (ER, PR,
CK5/6, CK17 and CK8) were similar in both areas (data not
shown). Silver in situ hybridisation confirmed HER2 amplification
in area 1 and lack of amplification in area 2, with sharp borders
between the two areas (Figure 4A). Allelic profiles obtained after
microdissection with D17S1840 showed only one allele in area
1 and only the other allele in area 2, consistent with subclonal
heterogeneity (Figure 4B). For D17S250, one new allele was
observed in the non-microdissected tumour, as well as in areas
1 and 2 (Figure 4B), strongly suggesting that areas 1 and 2 are
derived from a common tumour cell. Allelic profiles with the three
other microsatellites were almost similar in both areas. The
analysis of the X-chromosome methylation pattern was not
informative since it showed inactivation of the same X chromo-
some in both areas (data not shown).
DISCUSSION
Selection of patients for trastuzumab treatment is primarily
performed by IHC using HercepTest, CB11 or 4B5 antibody, as
recommended (Birner et al, 2001; Wolff et al, 2007). HER2
immunostaining is easy to perform, available as a standard method
in pathology laboratories, widely applicable (on FFPE specimens),
very reliable (Lebeau et al, 2010; Purdie et al, 2010) and relatively
inexpensive, but is only a semi-quantitative method. Yet, in 3–15%
of cases (Dendukuri et al, 2007), IHC is equivocal and further
analyses are required, leading to the usual IHCþFISH association.
Like IHC, FISH is a semi-quantitative morphological method but
with higher costs and need of specialised expertise and equipment.
In the context of HER2 status assessment, Q-RT–PCR could also
be a useful option and an alternative to the current IHCþFISH
procedure. Several studies have already compared IHC and
Q-RT–PCR (Cronin et al, 2004; Ginestier et al, 2004; Gjerdrum et al,
2004; Bossard et al, 2005; Esteva et al, 2005; Vanden Bempt
et al, 2005; Vinatzer et al, 2005; Bergqvist et al, 2007; Kostopoulou
et al, 2007; Barberis et al, 2008; Cuadros et al, 2010) (Table 1).
These reports showed good overall concordance (82–100%) with
frozen or FFPE specimen, and mostly without microdissection, but
in small patient series. Moreover, HER2 mRNA evaluation was
shown to be a fast, reliable and cost-effective alternative to the
IHCþFISH procedure and also correlated with overall survival
and disease-free survival (Vinatzer et al, 2005).
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Figure 2 Analysis of 14 equivocal and 12 discordant cases (n¼26). (A) Comparison of seven different methods (columns) in the 26 discordant or
equivocal cases (lines): determination at the protein level by IHC – CB11, polyclonal A0485 and 4B5 antibodies, at the mRNA level by Q-RT–PCR, at the
DNA level by SISH, FISH and Q-PCR. A negative result is symbolised in blue, positive in red and equivocal in green. Final HER2 status is based on the result
of all seven methods: positive if there were majority of positive results, negative if there were majority of negative results, and unclassified in other situations.
(B) Illustration of discordant case #17: Upper panel: immunohistochemical staining for HER2 with CB11, A0485 and 4B5 antibodies and indirect
immunoperoxydase visualisation (magnification  250). Lower panel: SISH staining with HER2 probe, CEN17 probe and FISH staining with HER2 probe in
green and CEN17 probe in orange. (magnification  400).
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sIn this prospective study of 466 breast tumours comparing IHC
and Q-RT–PCR determination of HER2 status, we show that
Q-RT–PCR was very strongly correlated with IHC (overall
concordance 97.3%). In the 12 discordant cases, Q-RT–PCR was
not as powerful as IHC to predict the final HER2 status determined
by five other methods, with seven and one false negative cases and
two and one false positive cases for Q-RT–PCR and IHC,
respectively. However, four cases (Figure 2A, cases #23, 24, 25
and 26) among the seven Q-RT–PCR false negative cases had
ratios very close to the cut-off value, suggesting that tumour cells
dilution could explain the discrepancy. Note that in cases #23, 24
and 25, only Q-RT–PCR method was unable to predict the HER2
positivity, perhaps because mRNA analysis can be tricky in
borderline cases. Similarly, in the two false positive cases (#1 and #2),
the ratio was also close over the cut-off value and #1 presented a
small in situ component, although evaluated to be o10%.
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Figure 3 Analysis of case A heterogeneity. (A) Schematic representation of case A with distinction of area 1 (HER2þ) and area 2 (HER2 ): H&E
section, immunohistochemical stainings for HER2, ER, PR, CK5/6, CK8 and SISH evaluation of HER2 (magnification  250). (B) Analysis of X-chromosome
methylation pattern (HUMARA): allelic profiles for the total tumour and microdissected areas 1 and 2 are shown, before HpaII (upper line) and after HpaII
(lower line) digestion. Differences between the two areas are represented by arrows.
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highly predictive of the final HER2 status in 10 out of 13 cases. These
results thus validate the use of Q-RT–PCR as alternative to FISH in
IHC 2þ cases. Overall, Q-RT–PCR and IHC had statistically similar
efficiency for predicting HER2 status in the overall 466 cases we
studied (452 out of 466 and 449 out of 466, respectively).
Q-RT–PCR is quick, easy to perform, quantitative and has no
inter-observer variability. However, dilution of tumour genomic
material with non-neoplastic tissue or presence of in situ
component are well-known drawbacks of Q-RT–PCR, so that
microscopical control of the sample is particularly crucial prior to
molecular extraction. If expert pathological selection is performed,
microdissection can clearly be avoided (Gjerdrum et al, 2004).
Since Q-RT–PCR can be performed with as little as 100ng RNA,
the corresponding amount of frozen tissue is easily obtained even
with 14G or 16G fine-needle biopsies of breast tumours (O’Flynn
et al, 2010), although a frozen tissue workflow has to be organised.
While we determined here the mRNA level using frozen tissues, several
reports demonstrated also the good HER2 mRNA/protein concordance
in FFPE samples (Cronin et al, 2004; Barberis et al, 2008).
Immunohistochemistry and Q-RT–PCR are, therefore, two
complementary approaches, with an excellent overall sensitivity
and with almost no equivocal cases. Measurement of tumour cell
percentage and morphological HER2 assessment are done by H&E
and IHC stainings, while quantitative HER2 assessment is obtained
by Q-RT–PCR, for moderate costs (Vinatzer et al, 2005). Indeed, the
combination of IHCþQ-RT–PCR has an estimated cost of 157.27
euros, compared with 525.68 euros for IHCþFISH determination
(Vinatzer et al, 2005). The association of these two techniques in
breast cancer would be useful for patient care, each technique
controlling and complementing the other one. However, it is not
possible to draw similar conclusions in gastroesophageal cancers,
now often tested for HER2 status, since these tumours might be
more heterogeneous than breast tumours and the use of molecular
techniques in this field of pathology should be evaluated.
One rare but significant finding in our study was that a few
tumours (12 out of 466) had a highly discordant HER2 status
depending on the methods used. One of these discordant cases
(tumour #4) showed chromosome 17 polysomy that is well known
to complicate HER2 status analysis (Dal Lago et al, 2006). Another
case (tumour #17) showed highly discordant results among the
three antibodies used for IHC, although stainings had been
performed on three adjacent tissue sections, maybe reflecting
inappropriate fixation of the sample. For the other 10 discordant
cases, only hypotheses can be drawn to explain these discrepan-
cies: some of these cases could have a true borderline HER2 status;
therefore, being considered negative or positive with only slight
technical sensitivity changes.
Intra-tumour heterogeneity may also explain some of these
discrepancies, even when the analyses are performed on close
tissue areas. We describe here two cases that are typical examples of
regional HER2 intra-tumour heterogeneity. In case A, methylation
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Figure 4 Analysis of case B heterogeneity. (A) Schematic representation of case B with distinction of areas 1 and 2: in H&E section, in
immunohistochemical stainings for HER2 and SISH evaluation of HER2 (magnification  250). (B) Analysis of allelic profile using D17S1840 and D17S250
microsatellites after microdissection of areas 1 and 2. The profile in grey represents the normal counterpart and the profile in green or blue the different
tumour areas and the total tumour before microdissection. The arrows point to loss of heterozygosity (D17S1840) or to new alleles (D17S250).
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sof one X chromosome in HER2þ area and methylation of the other
Xc h r o m o s o m ei nH E R 2   area strongly suggest the existence of two
distinct tumours, deriving from two distinct initiating tumour cells.
Case A would be, therefore, like the so-called ‘collision tumours’
described by pathologists (Isaka et al, 2007; Kleist et al, 2010) all
characterised by the simultaneous occurrence at the same place and
at the same time of two tumours with distinct histological types. In
case B, the presence in both HER2þ and HER2  areas of shared
new allelic abnormalities strongly suggests that the tumour derives
from a single clone, HER2þ area and HER2  area being two
different subclones. Therefore, in case B, HER2 amplification may
be a progression event in a clonal tumour cell population, as
recently reported (Hanna et al, 2007; Kostopoulou et al, 2007; Cottu
et al, 2008; Apple et al,2 0 0 9 ) .
In conclusion, we demonstrate an excellent concordance
between IHC and Q-RT–PCR for HER2 status assessment in
breast tumours. Rare discordances may be due sometimes to intra-
tumour heterogeneity. The association of these two methods in
IHC equivocal cases or even in all tumours may be a reliable and
moderate-cost strategy for HER2 status assessment. The quanti-
tative nature of Q-RT–PCR could also provide clinically relevant
informations, allowing tailored treatment according to the
amplitude of HER2 overexpression in breast cancers.
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